LENZ Therapeutics Inc
LENZ16.890USD
-0.730-4.14%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
482.86MMarket Cap
LossP/E TTM
More Details of LENZ Therapeutics Inc Company
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Info
Ticker SymbolLENZ
Company nameLENZ Therapeutics Inc
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Number of employees42
Security typeOrdinary Share
Fiscal year-endJun 25
Address- -
City- -
Stock exchangeNASDAQ OMX - NASDAQ BASIC
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolLENZ
IPO dateJun 25, 2021
CEOSchimmelpennink (Evert)
Company Executives of LENZ Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
Other
56.13%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
Other
56.13%
Shareholder Types
Shareholders
Proportion
Venture Capital
34.49%
Investment Advisor
26.63%
Hedge Fund
23.81%
Investment Advisor/Hedge Fund
15.67%
Individual Investor
2.52%
Research Firm
2.01%
Pension Fund
0.17%
Bank and Trust
0.13%
Insurance Company
0.02%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.27%
iShares U.S. Pharmaceuticals ETF
Proportion0.22%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Biotechnology ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Date
Type
Ratio
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
FAQs
Who are the top five shareholders of LENZ Therapeutics Inc?
The top five shareholders of LENZ Therapeutics Inc are:
RA Capital Management, LP holds 4.18M shares, accounting for 14.65% of the total shares.
Alpha Wave Global, LP holds 3.61M shares, accounting for 12.66% of the total shares.
Versant Ventures holds 2.88M shares, accounting for 10.10% of the total shares.
Ridgeback Capital Management, L.P. holds 1.95M shares, accounting for 6.84% of the total shares.
The Vanguard Group, Inc. holds 1.29M shares, accounting for 4.52% of the total shares.
RA Capital Management, LP holds 4.18M shares, accounting for 14.65% of the total shares.
Alpha Wave Global, LP holds 3.61M shares, accounting for 12.66% of the total shares.
Versant Ventures holds 2.88M shares, accounting for 10.10% of the total shares.
Ridgeback Capital Management, L.P. holds 1.95M shares, accounting for 6.84% of the total shares.
The Vanguard Group, Inc. holds 1.29M shares, accounting for 4.52% of the total shares.
What are the top three shareholder types of LENZ Therapeutics Inc?
The top three shareholder types of LENZ Therapeutics Inc are:
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures
How many institutions hold shares of LENZ Therapeutics Inc (LENZ)?
As of 2025Q3, 267 institutions hold shares of LENZ Therapeutics Inc, with a combined market value of approximately 30.95M, accounting for 100.67% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.78%.
What is the biggest source of revenue for LENZ Therapeutics Inc?
In --, the -- business generated the highest revenue for LENZ Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
